Tetrahydropyridoethers for treatment of amd

Abstract

A medication comprising tetrahydropyridoethers for use in the treatment of AMD.

1 . A medication comprising tetrahydropyridoethers for use in the treatment of AMD. 
     
     
         2 . A medication comprising tetrahydropyridoethers for use in the treatment of dry AMD. 
     
     
         3 . A medication comprising a compound according to the following formula I for use in the treatment of AMD or dry AMD 
       
         
           
           
               
               
           
         
         in which 
         R1 is methyl or hydroxymethyl, one of the substituents R2a and R2b is hydrogen and the other is hydroxy, methoxy, ethoxy, isopropoxy, methoxyethoxy or ethoxypropoxy, one of the substituents R3a and R3b is hydrogen and the other is hydroxy, methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, where R2a or R2b on the one hand and R3a or R3b on the other hand are not simultaneously hydroxy, and its salts. 
       
     
     
         4 . The medication for use in the treatment of AMD or dry AMD, comprising a compound of  claim 3 , in which R1 is methyl, one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, one of the substituents R3a and R3b is hydrogen and the other is hydroxy, and its salts. 
     
     
         5 . The medication for use in the treatment of AMD or dry AMD according to  claim 3 , in which R1 is methyl, one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, one of the substituents R3a and R3b is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, and its salts. 
     
     
         6 . The medication for use in the treatment of AMD or dry AMD according to  claim 3 , in which R3b is hydrogen. 
     
     
         7 . The medication for use in the treatment of AMD or dry AMD according to  claim 3 , in which R2a and R3b are hydrogen. 
     
     
         8 . The medication for use in the treatment of AMD or dry AMD according to  claim 3 , in which R2a is hydrogen and R2b is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, and its salts. 
     
     
         9 . The medication for use in the treatment of AMD or dry AMD according to  claim 3 , comprising a compound according to the following formula I* 
       
         
           
           
               
               
           
         
         in which R1 is methyl or hydroxymethyl, one of the substituents R2a and R2b is hydrogen and the other is hydroxy, methoxy, ethoxy, isopropoxy, methoxyethoxy or ethoxypropoxy, one of the substituents R3a and R3b is hydrogen and the other is hydroxy, methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, where R2a or R2b on the one hand and R3a or R3b on the other hand are not simultaneously hydroxy, and its salts. 
       
     
     
         10 . The medication for use in the treatment of AMD or dry AMD according to  claim 9 , in which R1 is methyl, one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, one of the substituents R3a and R3b is hydrogen and the other is hydroxy, and its salts. 
     
     
         11 . The medication for use in the treatment of AMD or dry AMD according to  claim 9 , in which R1 is methyl, one of the substituents R2a and R2b is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, one of the substituents R3a and R3b is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, and its salts. 
     
     
         12 . The medication for use in the treatment of AMD or dry AMD according to  claim 9 , in which R3b is hydrogen. 
     
     
         13 . The medication for use in the treatment of AMD or dry AMD according to  claim 9 , in which R2a and R3b are hydrogen. 
     
     
         14 . A medication comprising a compound according to the following formula II* for use in the treatment of AMD or dry AMD 
       
         
           
           
               
               
           
         
         In which one of the substituents Ra and Rb is hydrogen and the other is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, and its salts. 
       
     
     
         15 . The medication for use in the treatment of AMD or dry AMD, comprising a compound of  claim 14 , in which Ra is hydrogen and Rb is methoxy, ethoxy, isopropoxy, methoxyethoxy or methoxypropoxy, and its salts. 
     
     
         16 . The medication for use in the treatment of AMD or dry AMD according to  claim 3 , which is (7R,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine and its salts or (7R,8R,9R)-2,3-Dimethyl-7-ethoxy-8-hydroxy-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine and its pharmacologically acceptable salts for the treatment of AMD or dry AMD.